Changes in Hong Kong stocks | Yasheng Pharmaceutical-B (06855) rose more than 4%, APG-2449 was approved to carry out phase III clinical research and listing in the US is expected to open a new stage

The Zhitong Finance App learned that Yasheng Pharmaceutical-B (06855) rose by more than 4%, reaching a three-year high of HK$46.45. As of press release, it rose 4.62% to HK$46.45, with a turnover of HK$73.885,700.

According to the news, Yasheng Pharmaceutical recently announced that the company's original Class 1 new drugs, APG2449, FAK/ALK/ROS1 triple tyrosine kinase inhibitors (TKI), have obtained clinical trial approval from the National Drug Administration (NMPA) Drug Evaluation Center (CDE), and will conduct phase III clinical studies on second-generation anaplastic lymphoma kinase (ALK) TKI resistant or intolerant patients with advanced or locally advanced NSCLC.

Haitong International pointed out that in the field of hematoma, the company currently has two core products: olevatinib (BCR-ABL TKI) and Lisaftoclax (APG-2575, BCL-2). We expect the two core products to reach risk-adjusted global sales of 17.67 billion yuan by 2033. The company's other targets in the research pipeline have first-in-class potential. It continues to explore the potential for various indications such as hematomas, solid tumors, and non-tumors. It is recommended to focus on subsequent R&D progress. Furthermore, overseas cooperation has improved the financial situation, and listing in the US is expected to begin a new stage.